In Vivo: HPK1-IN-31(compound 5i) (p.o., 30 or 100 mpk twice daily, 14 days) inhibits tumour growth in the CT26 tumour-bearing female BALB/c mouse model and the MC38 tumour-bearing female C57BL/6 mouse model, and is followed by a significant effect when combined with anti-PD-1 monotherapy. The pharmacokinetic parameters of HPK1-IN-31(compound 5i)in Mice and Beagles